Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P DOMINGO

Showing results (251-260 of 276) with videos related to

Pageof 28
Sort By:
HIV Medicine|April 20, 2016
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavirJ Rojas, M Lonca, A Imaz, et al.
The New England Journal of Medicine|February 15, 2001
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98J C Lopez Bernaldo de Quiros, J M Miro, J M Peña, et al.
JAMA|August 13, 1997
Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance GroupN Barquet, P Domingo, J A Caylà, et al.
AIDS (London, England)|September 8, 2001
Drug resistance in patients experiencing early virological failure under a triple combination including indinavirO Gallego, C de Mendoza, M J Pérez-Elías, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2015
Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicityC Morén, M Bañó, I González-Casacuberta, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2021
Evolution of notified sexually transmitted infections in Barcelona during the first wave of the COVID-19 pandemicG Martin-Ezquerra, P Monreal, L Mercuriali, et al.
HIV Clinical Trials|March 11, 2011
Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant statusJ A Pérez-Molina, I Suárez-Lozano, A Del Arco, et al.
HIV Clinical Trials|April 19, 2012
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissueS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|January 15, 2014
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavirE Martinez, A Gonzalez-Cordon, E Ferrer, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 4, 2000
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study GroupD Podzamczer, J M Miró, E Ferrer, et al.
Pageof 28

Showing results (251-260 of 276) with videos related to

Sort By:
Pageof 28
HIV Medicine|April 20, 2016
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavirJ Rojas, M Lonca, A Imaz, et al.
The New England Journal of Medicine|February 15, 2001
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98J C Lopez Bernaldo de Quiros, J M Miro, J M Peña, et al.
JAMA|August 13, 1997
Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance GroupN Barquet, P Domingo, J A Caylà, et al.
AIDS (London, England)|September 8, 2001
Drug resistance in patients experiencing early virological failure under a triple combination including indinavirO Gallego, C de Mendoza, M J Pérez-Elías, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2015
Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicityC Morén, M Bañó, I González-Casacuberta, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2021
Evolution of notified sexually transmitted infections in Barcelona during the first wave of the COVID-19 pandemicG Martin-Ezquerra, P Monreal, L Mercuriali, et al.
HIV Clinical Trials|March 11, 2011
Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant statusJ A Pérez-Molina, I Suárez-Lozano, A Del Arco, et al.
HIV Clinical Trials|April 19, 2012
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissueS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|January 15, 2014
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavirE Martinez, A Gonzalez-Cordon, E Ferrer, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 4, 2000
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study GroupD Podzamczer, J M Miró, E Ferrer, et al.
Pageof 28